Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France14. May 2020|In Portfolio News|By eazee-designstudioThemis and ABL Europe, a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), a subsidiary of the French bioindustrial group Institut Mérieux, announced today that they have signed an agreement under which ABL will manufacture Themis’ vaccine candidate in preparation for clinical trials. The vaccine is being developed using a proprietary measles virus vaccine platform technology, which is licensed exclusively to Themis by the world-renowned Institut Pasteur in Paris. PrevNext
